- AmerisourceBergen (NYSE:ABC) initiated with Outperform rating and $105 (12% upside) price target by Evercore ISI.
- Arbutus Biopharma (NASDAQ:ABUS) initiated with Buy rating and $10 (82% upside) price target by B. Riley.
- AxoGen (NASDAQ:AXGN) initiated with Overweight rating and $37 (29% upside) price target by Cantor Fitzgerald.
- Becton, Dickinson and Company (NYSE:BDX) initiated with Overweight rating and $260 (18% upside) price target by Keybanc.
- Bruker (NASDAQ:BRKR) initiated with Buy rating and $42 (20% upside) price target by BTIG Research.
- Cardinal Health (NYSE:CAH) initiated with Neutral rating and $67 (5% upside) price target by Evercore ISI.
- Cerus (NASDAQ:CERS) initiated with Overweight rating and $5 (34% upside) price target by Cantor.
- CytomX Therapeutics (NASDAQ:CTMX) initiated with Buy rating and $40 (74% upside) price target by Citigroup (NYSE:C).
- Quest Diagnostics (NYSE:DGX) initiated with Neutral rating and $103 (4% upside) price target by Evercore ISI.
- Boston Scientific (NYSE:BSX) upgraded to Top Pick with a $31 (24% upside) price target by RBC.
- CVS Health (NYSE:CVS) upgraded to Overweight with an $88 (17% upside) price target by Morgan Stanley (NYSE:MS).
- AngioDynamics (NASDAQ:ANGO) downgraded to Hold by Craig-Hallum.
- Celgene (NASDAQ:CELG) downgraded to Neutral with a $120 (12% upside) price target by BofA/Merrill Lynch.
- Now read: Cardinal Health: In The Middle Of The Storm
Original article